A comprehensive resource on EU regulatory information for investigators in gene therapy clinical research and advanced therapy medicinal products

Human Gene Therapy

Volumn 24, Issue 1, 2013, Pages 12-18

  Cohen Haguenauer, Odile ^a,b  

^a SAINT LOUIS HOSPITAL   (France)

^b Ecole Normale Superieure de Cachan   (France)

Author keywords

[No Author keywords available]

Indexed keywords

NUCLEIC ACID; RECOMBINANT NUCLEIC ACID; UNCLASSIFIED DRUG;

ADVANCED THERAPY MEDICINAL PRODUCT; CELL ENGINEERING; CELL THERAPY; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); DNA MODIFICATION; EUROPEAN UNION; GENE DELETION; GENE SEQUENCE; GENE THERAPY; GENETIC REGULATION; HEALTH CARE POLICY; HERBAL MEDICINE; HUMAN; MEDICAL DOCUMENTATION; PRACTICE GUIDELINE; REVIEW; TISSUE ENGINEERING;

BIOLOGICAL AGENTS; BIOTECHNOLOGY; CLINICAL TRIALS AS TOPIC; EUROPEAN UNION; GENETIC THERAPY; GOVERNMENT REGULATION; RESEARCH; THERAPIES, INVESTIGATIONAL; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84872778533     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2012.2525     Document Type: Review

References (18)

1. CliniGene NoE. European network for the advancement of clinical gene transfer and therapy (EC-FP6-NoE). Available at www.clinigene.eu (accessed November 2012).
2. Cohen-Haguenauer, O. (2012a). Centralised regulation of gene therapy in europe. In The CliniBook: Clinical Gene Transfer State-of-the-Art. O. Cohen-Haguenauer, ed. (EDK, Paris), pp. 504-516.
3. Cohen-Haguenauer, O. (2012b). The necessity for data sharing towards advancement of clinical translation; building up sample IMPD and substantiating master files. In The CliniBook: Clinical Gene Transfer State-of-the-Art. O. Cohen-Haguenauer, ed. (EDK, Paris) pp. 517-527.
4. Corrigan-Curay, J., Cohen-Haguenauer, O., O'Reilly, M., et al. (2012). Challenges in vector and trial design using retroviral vectors for long-term gene correction in hematopoietic stem cell gene therapy: summary of a symposium sponsored by the NIH Office of Biotechnology Activities and the EC DGresearch NoE for the Advancement of Clinical Gene Transfer and Therapy. Mol. Ther. 20, 1084-1094.
5. European Commission, DG Health and Consumers. [a] Advanced therapies medicinal products (ATMPs) definitions are placed under EU-regulation: Directive 2009/120/EC of 14 September 2009 amending Directive 2001/83/EC. Available at http://ec.europa.eu/health/documents/eudralex/vol-1/index- en.htm (accessed July 2012).
6. European Commission, DG Health and Consumers. [b] Eudralex Vol 1, pharmaceuticals legislation, medicinal products for human use. Manipulation listed in Annex I to Regulation (EC) No 1394/2007, first indent of Article 2.1.c. Available at http://ec.europa.eu/health/documents/eudralex/vol-1/index- en.htm (accessed on July 2012).
7. European Commission, DG Health and Consumers. [c] Orphan Medicinal Products: the EU regulation on orphan medicinal products. Regulation (EC) No 141/2000. Available at http://ec.europa.eu/health/human-use/orphan-medicines/ index-en.htm (accessed November 2012).
8. European Commission, DG Health and Consumers. [d] Medicinal products for human use. Clinical trials regulation in Europe. Available at http://ec.europa.eu/health/human-use/ clinical-trials/index-en.htm (accessed July 2012).
9. European Commission, DG Health and Consumers. [e] Public Health. Available at http://ec.europa.eu/health/index-en.htm (accessed July 2012).
10. European Medicines Agency. [a] Advanced therapies. Available at www.ema.europa.eu/ema/index.jsp?curl=pages/special-topics/general/ general-content-000504.jsp&mid=WC0b01ac 058050f347 (accessed July 2012).
11. European Medicines Agency. [b] Committee for Medicinal Products for Human Use (CHMP). Available at www.ema.europa.eu/ema/index.jsp?curl=pages/about-us/ general/general- content-000094.jsp&mid=WC0b01ac0580028c79 (accessed July 2012).
12. European Medicines Agency. [c] Community clinical trial system (EudraCT) public home page. https://eudract.ema.europa.eu/ (accessed July 2012).
13. European Medicines Agency. [d] Draft guideline on the riskbased approach according to Annex I, part IV of Directive 2001/83/EC applied to ATMPs. EMA/CAT/CPWP/686637/2011. Available at www.ema.europa.eu/docs/en-GB/document- library/Scientific-guideline/2012/01/WC500120989.pdf (accessed July 2012).
14. European Parliament and Council. Regulation (EC) No 1901/ 2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/ EC, Directive 2001/83/EC and Regulation (EC) No 726/2004. Available at http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2006:378:0001:0019: en:PDF
15. Kent, A., King, N.M., and Cohen-Haguenauer, O. (2011) Toward a proportionate regulatory framework for gene transfer: a patient group-led initiative. Hum. Gene Ther. 22, 126-134.
16. King, N.M., and Cohen-Haguenauer, O. (2008) En route to ethical recommendations for gene transfer clinical trials. Mol. Ther. 16, 432-438.
17. PreLex. Monitoring of the decision-making process between institutions. Available at http://ec.europa.eu/prelex/apcnet.cfm?CL=en (accessed December 2012).
18. Schneider, C.K., Salmikangas, P., Jilma, B., et al. (2010). Challenges with advanced therapy medicinal products and how to meet them. Nat. Rev. Drug Discov. 9, 195-201.